---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-012316"
form_type: "8-K"
ticker: "CURX"
cik: "0002025942"
company_name: "Curanex Pharmaceuticals Inc"
filed_at: "2025-08-26T23:59:59+00:00"
generated_at: "2026-05-17T10:04:35.828306+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Curanex Pharmaceuticals prices IPO of 3.75M shares at $4.00/share, gross $15M

## Summary
- Gross proceeds $15M from 3.75M shares at $4.00/share; net proceeds ~$12.1M after underwriting discounts and expenses.
- Shares expected to begin trading on Nasdaq (CURX) on Aug 26, 2025; close expected Aug 27, 2025.
- Underwriters have 45-day option to purchase up to 562,500 additional shares to cover over-allotments.
- Proceeds to fund Phyto-N (ulcerative colitis) development, GLP toxicology/pharmacokinetic studies, IND submission, and working capital.
- Lead underwriter: Dominari Securities; co-underwriters: Pacific Century Securities and Revere Securities.

## SEC filing metadata
- accession: 0001493152-25-012316
- form_type: 8-K
- ticker: CURX
- cik: 0002025942
- company_name: Curanex Pharmaceuticals Inc
- filed_at: 2025-08-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2025942/000149315225012316/0001493152-25-012316-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2025942/000149315225012316/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-012316
- JSON: https://secwatch.observer/filing/0001493152-25-012316.json
- Plain text: https://secwatch.observer/filing/0001493152-25-012316.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.